Eric Levi

Eric Levi is an associate in Goodwin’s Intellectual Property Litigation practice who focuses on patent litigation and breach of contract actions. He has served clients in matters involving a broad range of technologies, including pharmaceuticals and electronic devices.

Eric also maintains an active pro bono practice, representing veterans in their appeal of unfavorable service-connected disability decisions to the U.S. Court of Appeals for Veterans Claims.

Eric has experience in complex litigation, arbitration and negotiation, representing both patent owners and patent challengers. Eric's representative matters include:

• Pharmaceutical companies in Hatch-Waxman and 505(b)(2) actions, including District of Delaware bench trials regarding validity and infringement of an oncology drug, cabazitaxel, and an inhaled dry powder formulation of treprostinil
• Pharmaceutical company in an international arbitration action
• Data management and SaaS company in a patent infringement action regarding validity and infringement of data collection platform
• Petroleum distribution and marketing company in a patent infringement appeal to the U.S. Court of Appeals for the Federal Circuit regarding petroleum blending
• Animal health company in an intellectual property advisement and business development matter
• Pharmaceutical company in a declaratory judgment action and arbitration regarding patent invalidity and unenforceability*
• Patentee in district court patent infringement and PTAB actions regarding an electronic smoking device*
• Patentee in district court patent infringement action regarding a method for presenting a user-specific video feed*
• Insured in breach of contract and premises liability actions*
• Veterans through the process of appealing unfavorable service-connected disability ratings to the U.S. Court of Appeals for Veterans Claims

*Denotes experience prior to joining Goodwin.

While attending law school, Eric served as a judicial intern to the Honorable Pauline Newman of the U.S. Court of Appeals for the Federal Circuit. Eric was also a student attorney in the Glushko Samuelson IP Clinic and member of the Alternative Dispute Resolution Honor Society, American University Law Review, and Juvenile Justice Mentorship Society, and served as an Articles Editor for the Health Law and Policy Brief. Prior to joining Goodwin, Eric was an associate at Cozen O'Connor, where his work focused on intellectual property and insurance litigation.

Prior to entering the legal field, Eric was an engineer at Hospira, supporting all aspects of aseptic and terminally sterilized parenteral drug manufacturing. Eric has also enjoyed coaching tennis in New Jersey, North Carolina, and Washington, D.C.

Eric is a board member of the Burg-Levi Education Foundation, and member of the Pauline Newman Intellectual Property American Inn of Court, Federal Circuit Bar Association, ABA Young Lawyers Division, ABA Judicial Intern Opportunity Program, American Intellectual Property Law Association, American Institute of Chemical Engineers, New Jersey Bar Association, and DC Bar Association. Eric is also a Contributor to Goodwin’s “Guide to Biosimilars Litigation and Regulation in the U.S.,” 2022-2023 and 2023-2024 eds., published by Thomson Reuters, as well as “Biosimilars Litigation and Client Counseling,” 2023-2024 ed., published by the American Bar Association.

Eric’s recent publications and speaking engagements include:

• Special Contributor, “Antitrust Litigation and Product Liability Considerations” in “Biosimilars Litigation and Client Counseling,” published by the American Bar Association, forthcoming
• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Special Contributor, “Winning patent strategies for biosimilars” in “New Frontiers of Pharma and Biotech IP Strategy: How to Navigate the Fast-Changing Life Sciences Landscape,” published by IAM, 2023 
• Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, 2022 
• Author, “Five Years after Form 18: Post-Iqbal–Twombly Rule 12(b)(6) and 12(c) Motions to Dismiss Patent Infringement Claims,” IPWATCHDOG, 2021 
• Speaker, “Patent Pools & Pledges in the Fight Against COVID-19 (2020),” Webinar, 2020 
• Speaker, Summarily Affirmed, Fed. R. App. P. 36, 2019
• Author, ”Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics’ Manufacturing Processes,” 66 AM. U. L. REV. 911, 2017